[go: up one dir, main page]

MX2014015899A - Capsula de estradiol soluble para insercion por via vaginal. - Google Patents

Capsula de estradiol soluble para insercion por via vaginal.

Info

Publication number
MX2014015899A
MX2014015899A MX2014015899A MX2014015899A MX2014015899A MX 2014015899 A MX2014015899 A MX 2014015899A MX 2014015899 A MX2014015899 A MX 2014015899A MX 2014015899 A MX2014015899 A MX 2014015899A MX 2014015899 A MX2014015899 A MX 2014015899A
Authority
MX
Mexico
Prior art keywords
vaginal insertion
soluble estradiol
capsule
estradiol capsule
soluble
Prior art date
Application number
MX2014015899A
Other languages
English (en)
Other versions
MX358435B (es
Inventor
Brian A Bernick
Janice Louise Cacace
Julia M Amadio
Peter H R Persicaner
Thorsteinn Thorsteinsson
Original Assignee
Therapeuticsmd Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49769313&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2014015899(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from US13/684,002 external-priority patent/US8633178B2/en
Priority claimed from PCT/US2013/023309 external-priority patent/WO2013112947A1/en
Priority claimed from US13/843,428 external-priority patent/US9301920B2/en
Application filed by Therapeuticsmd Inc filed Critical Therapeuticsmd Inc
Publication of MX2014015899A publication Critical patent/MX2014015899A/es
Publication of MX358435B publication Critical patent/MX358435B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/02—Suppositories; Bougies; Bases therefor; Ovules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/04—Drugs for genital or sexual disorders; Contraceptives for inducing labour or abortion; Uterotonics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Urology & Nephrology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pregnancy & Childbirth (AREA)
  • Diabetes (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)
  • Infusion, Injection, And Reservoir Apparatuses (AREA)

Abstract

De conformidad con varias modalidades de la presente descripción, se presentan formulaciones farmacéuticas que comprenden estradiol solubilizado. En varias modalidades, dichas formulaciones se encapsulan en cápsulas blandas que pueden insertarse por vía vaginal para el tratamiento de la atrofia vulvovaginal.
MX2014015899A 2012-06-18 2013-06-18 Capsula de estradiol soluble para insercion por via vaginal. MX358435B (es)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201261661302P 2012-06-18 2012-06-18
US201261662265P 2012-06-20 2012-06-20
US13/684,002 US8633178B2 (en) 2011-11-23 2012-11-21 Natural combination hormone replacement formulations and therapies
US201261745313P 2012-12-21 2012-12-21
PCT/US2013/023309 WO2013112947A1 (en) 2012-01-26 2013-01-25 Transdermal hormone replacement therapies
US13/843,428 US9301920B2 (en) 2012-06-18 2013-03-15 Natural combination hormone replacement formulations and therapies
PCT/US2013/046443 WO2013192249A1 (en) 2012-06-18 2013-06-18 Soluble estradiol capsule for vaginal insertion

Publications (2)

Publication Number Publication Date
MX2014015899A true MX2014015899A (es) 2015-03-03
MX358435B MX358435B (es) 2018-08-03

Family

ID=49769313

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2014015899A MX358435B (es) 2012-06-18 2013-06-18 Capsula de estradiol soluble para insercion por via vaginal.
MX2018009466A MX393195B (es) 2012-06-18 2013-06-18 Capsula de estradiol soluble para insercion por via vaginal

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2018009466A MX393195B (es) 2012-06-18 2013-06-18 Capsula de estradiol soluble para insercion por via vaginal

Country Status (13)

Country Link
EP (2) EP2861073B1 (es)
JP (3) JP6397402B2 (es)
AU (3) AU2013277234B2 (es)
BR (1) BR112014031914B1 (es)
CA (1) CA2876968C (es)
ES (1) ES2869250T3 (es)
HR (1) HRP20210861T1 (es)
HU (1) HUE055275T2 (es)
IL (1) IL236359B (es)
MX (2) MX358435B (es)
PL (1) PL2861073T3 (es)
RU (2) RU2020140867A (es)
WO (1) WO2013192249A1 (es)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3936133A1 (en) 2011-11-23 2022-01-12 TherapeuticsMD, Inc. Natural combination hormone replacement formulations and therapies
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US20150196640A1 (en) 2012-06-18 2015-07-16 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US20130338122A1 (en) 2012-06-18 2013-12-19 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10206932B2 (en) 2014-05-22 2019-02-19 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
KR20170040209A (ko) 2014-07-29 2017-04-12 쎄러퓨틱스엠디, 인코퍼레이티드 경피 크림
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
MX384850B (es) * 2015-12-07 2025-03-14 Therapeuticsmd Inc Composiciones farmacéuticas de estradiol insertadas por vía vaginal y métodos.
WO2017105512A1 (en) * 2015-12-18 2017-06-22 Proinvet Innovations S.A. Formulations and methods for controlling the reproductive cycle and ovulation
US10286077B2 (en) 2016-04-01 2019-05-14 Therapeuticsmd, Inc. Steroid hormone compositions in medium chain oils
CA3020153A1 (en) 2016-04-01 2017-10-05 Therapeuticsmd, Inc. Steroid hormone pharmaceutical composition
JP7745545B2 (ja) * 2019-10-31 2025-09-29 アール．ピー．シェーラー テクノロジーズ，エルエルシー 坐剤カプセル

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US694192A (en) * 1901-04-20 1902-02-25 William C Rastetter Vehicle-wheel.
IT1090703B (it) * 1976-12-03 1985-06-26 Scherer Ltd R P Perfezionamento nelle composizioni utili quali veicolo per farmaci
US4384096A (en) * 1979-08-27 1983-05-17 The Dow Chemical Company Liquid emulsion polymers useful as pH responsive thickeners for aqueous systems
FR2668945B1 (fr) * 1990-11-12 1993-02-19 Theramex Nouveau procede de cristallisation des substances organiques et les composes ainsi obtenus.
GB9405304D0 (en) * 1994-03-16 1994-04-27 Scherer Ltd R P Delivery systems for hydrophobic drugs
FR2728464B1 (fr) * 1994-12-22 1997-04-30 Innothera Lab Sa Forme galenique unitaire, son procede d'obtention et ses utilisations
FR2739558B1 (fr) 1995-10-05 1997-11-28 Innothera Lab Sa Forme galenique unitaire pour hormonotherapie locale de la secheresse vaginale
GB9608719D0 (en) 1996-04-26 1996-07-03 Scherer Ltd R P Pharmaceutical compositions
US6018033A (en) 1997-05-13 2000-01-25 Purdue Research Foundation Hydrophilic, hydrophobic, and thermoreversible saccharide gels and forms, and methods for producing same
NZ330726A (en) * 1998-06-18 2000-10-27 Dec Res Intra-vaginal delivery unit or composition containing a cyclodextrin which improves absorbtion of 17-beta oestradiol or oestradiol benzoate
US7374779B2 (en) * 1999-02-26 2008-05-20 Lipocine, Inc. Pharmaceutical formulations and systems for improved absorption and multistage release of active agents
US6294192B1 (en) * 1999-02-26 2001-09-25 Lipocine, Inc. Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents
US20030083286A1 (en) * 2001-08-22 2003-05-01 Ching-Leou Teng Bioadhesive compositions and methods for enhanced intestinal drug absorption
US20050042268A1 (en) * 2003-07-16 2005-02-24 Chaim Aschkenasy Pharmaceutical composition and method for transdermal drug delivery
US20060134188A1 (en) * 2004-12-20 2006-06-22 Hans-Peter Podhaisky Transdermal pharmaceutical preparation with a progesterone A-specific ligand (PRASL) as active ingredient
EP1846040A2 (en) * 2005-01-28 2007-10-24 Collegium Pharmaceutical, Inc. Non-ionic non-aqueous vehicles for topical and oral administration of carrier-complexed active agents
AU2006330846A1 (en) * 2005-12-27 2007-07-05 Teva Women's Health, Inc. Conjugated estrogen compositions, applicators, kits, and methods of making and use thereof
AU2007224006A1 (en) * 2006-03-07 2007-09-13 Novavax, Inc. Nanoemulsions of poorly soluble pharmaceutical active ingredients and methods of making the same
FR2900052B1 (fr) * 2006-04-19 2011-02-18 Galderma Sa Composition comprenant au moins une phase aqueuse et au moins une phase grasse comprenant de l'ivermectine
US20070287789A1 (en) * 2006-06-07 2007-12-13 Stephen Ray Jones Bleed-resistant colored microparticles
CN101474167A (zh) * 2009-01-23 2009-07-08 西安德天药业股份有限公司 雌二醇阴道用胶囊的制备方法
US9301920B2 (en) * 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
EP3936133A1 (en) * 2011-11-23 2022-01-12 TherapeuticsMD, Inc. Natural combination hormone replacement formulations and therapies

Also Published As

Publication number Publication date
AU2013277234A1 (en) 2015-01-22
JP2020100642A (ja) 2020-07-02
JP6682127B2 (ja) 2020-04-15
MX358435B (es) 2018-08-03
WO2013192249A1 (en) 2013-12-27
MX393195B (es) 2025-03-24
RU2740059C2 (ru) 2020-12-31
AU2013277234B2 (en) 2017-04-27
AU2017208300A1 (en) 2017-08-17
RU2020140867A (ru) 2021-06-10
JP2015519405A (ja) 2015-07-09
EP2861073B1 (en) 2021-04-14
CA2876968A1 (en) 2013-12-27
HUE055275T2 (hu) 2021-11-29
JP2018199711A (ja) 2018-12-20
EP2861073A1 (en) 2015-04-22
EP3909586A1 (en) 2021-11-17
HRP20210861T1 (hr) 2021-09-17
BR112014031914B1 (pt) 2021-12-14
BR112014031914A2 (pt) 2017-06-27
PL2861073T3 (pl) 2021-09-27
CA2876968C (en) 2022-09-13
IL236359A0 (en) 2015-02-26
JP6397402B2 (ja) 2018-09-26
IL236359B (en) 2020-11-30
AU2019204653A1 (en) 2019-07-18
ES2869250T3 (es) 2021-10-25
RU2015100531A (ru) 2016-08-10
AU2019204653B2 (en) 2021-07-08
EP2861073A4 (en) 2015-12-23

Similar Documents

Publication Publication Date Title
MX393195B (es) Capsula de estradiol soluble para insercion por via vaginal
PH12015500727A1 (en) Pharmaceutical compositions
MX2018002301A (es) Composiciones de glucano y usos de las mismas.
TN2012000161A1 (en) Spiro-oxindole mdm2 antagonists
MX2015000813A (es) Composiciones liposómicas de inhibidores de proteasoma basadas en epoxicetona.
MX366899B (es) Nuevos compuestos.
MX2013004061A (es) Analogos de ciclosporina.
IN2013MU03583A (es)
MX2019012939A (es) Formulaciones que contienen linaclotida para administracion oral.
PH12015501096A1 (en) Composition for immediate and extended release
IN2014DN06737A (es)
MX2013004062A (es) Analogos de ciclosporina.
EP3250214A4 (en) High surface-area lyophilized compositions comprising arsenic for oral administration in patients
MX2016005092A (es) Composiciones farmaceuticas de estradiol insertadas en la vagina y metodos.
HK1215391A1 (zh) 使用胎盘细胞外基质治疗口腔病变
MX359713B (es) Composiciones mejoradas para la cicatrizacion de heridas que comprenden microesferas.
WO2013170086A3 (en) Formulations for the delivery of active ingredients
MX2013010415A (es) Tratamiento de la atrofia vaginal con nueva indicacion para la mirra.
IN2012DE00826A (es)
GB2501427A (en) A washing capsule for providing washing compositions to a machine
MX2022002614A (es) El uso de un pesario que comprende una capsula que contiene estradiol y un agente solubilizante para el tratamiento de la atrofia vulvovaginal.
IN2014DN07897A (es)
TN2010000445A1 (en) Oral and injectable formulations of tetracycline compounds
UA101054C2 (en) Veterinary preparation
UA92932C2 (ru) Ветеринарное средство для лечения и профилактики эндометритов

Legal Events

Date Code Title Description
FG Grant or registration